Recommended Free Tools
Yes, according to Kranthi Bathini, a WealthMills Securities analyst quoted by Business Today: he believes the pharma and healthcare sector still has room to run over the medium to long term. That is an investment opinion, not a measured forecast or a guarantee. The companies named alongside his view have different news and risks, and the interview does not rank them or identify a preferred stock.
What is Bathini’s view on the pharma rally?
In a Business Today interview published October 5, 2026, Bathini described the recent gains as a “fabulous rally for pharma as well as healthcare.” He said, “One can buy pharma stocks. Still there is steam left in the pharma stocks.” He framed that view for investors with a medium- to long-term horizon, saying consolidation or declines could offer an opportunity to them.
Those comments express Bathini’s outlook; they do not establish that prices will rise, indicate when a rally might continue, or amount to advice tailored to an individual investor. Business Today’s coverage gives no percentage return, index performance series, valuation measure or price target to quantify the rally or his expectations. Business Today’s interview coverage and its same-day article summarizing the remarks are the sources for this view.
What company news did the interview mention?
The interview’s company references are news points, not a like-for-like comparison of investment quality. The available reporting does not establish comparative valuations, earnings prospects, balance-sheet strength or expected returns for these stocks.
| Company | News described in the interview | What is established |
|---|---|---|
| Cipla | A regulatory issue tied to a warehouse licence. | Business Today reports the issue. The retrieved Cipla investor information page does not independently establish the exact matter, its procedural status, the facility involved or its consequences. |
| Sun Pharma | A positive update for its alopecia drug. | Sun Pharma’s official Regulation 30 disclosure listing includes a press release for LEQSELVI dated October 1, 2026. The listing confirms the release and date, but not detailed clinical or regulatory facts about the update. |
| Piramal Pharma | A Bayer arrangement is reported to end in December. | Business Today reports the arrangement ending; the available sources do not establish its precise terms, date or financial consequences. No revenue or earnings impact can be inferred from the report alone. |
| Aurobindo Pharma | Multiple growth triggers, with general references to acquisition and US FDA developments. | Business Today describes the developments broadly. Aurobindo’s official disclosure page lists 2026 disclosures, but the available material does not identify which specific milestones Bathini meant. |
How should investors interpret the comments?
Bathini’s stated thesis is sector-wide and horizon-specific: he sees possible opportunity in pharma and healthcare shares for investors prepared to look beyond short-term moves. It should not be read as a claim that every pharmaceutical company will benefit equally, or that a decline in any particular share is automatically a buying opportunity.
The interview does not name a preferred stock, compare the four companies on valuation or expected return, or provide a quantified forecast. Investors considering any of them would need to assess company-specific disclosures and risks, along with their own time horizon and capacity for loss. The cited company developments alone do not settle those questions.
Quick Recap
Best Value
Rank #4
- Used Book in Good Condition
Rank #2
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
